RxDoctor Payments Data

Ranjeet Bajwa

Optometrist · Lindsay, CANPI 1881841575

Payments from drug & device makers

$11,279in general payments, 2019–2025

Across 148 payments — averaging $76.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tarsus Pharmaceuticals, Inc.$7K
  • Oyster Point Pharma, Inc.$851
  • Sun Pharmaceutical Industries Inc.$714
  • Bausch & Lomb Americas Inc.$353
  • AbbVie$292
  • Dompe US, Inc.$256
  • plus $2K from 19 others

What the payments were for

  • Consulting fees$3,60032%
  • Speaking & faculty fees$1,35012%
  • Travel & lodging$1,25611%
  • Food & beverage$5,05445%
  • Gifts$190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,279 in reported general payments places this provider in the 95th percentile of 6,778 optometrist providers in California.

See all optometrist providers in California

Medicare billing

Part B allowed, 2024
$905,053
Medicare patients
1,092
Services billed
7,124

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine64$59,874
MieboPerfluorohexyloctane/Pf37$26,876
XiidraLifitegrast30$26,212
LumiganBimatoprost64$25,500
XdemvyLotilaner12$20,642
Cyclosporine29$20,497
RocklatanNetarsudil Mesylat/Latanoprost24$14,756
CequaCyclosporine11$12,814
VyzultaLatanoprostene Bunod13$9,758
SimbrinzaBrinzolamide/Brimonidine Tart14$4,152
Latanoprost182$2,114
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol18$1,034
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat34$814
Timolol Maleate85$751
Travoprost13$750

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$292$85,374128 claims
Bausch & Lomb Americas Inc.Miebo, Xiidra, Vyzulta$353$62,84680 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$6,930$20,64212 claims
Aerie Pharmaceuticals, Inc.Rocklatan$150$14,75624 claims
Sun Pharmaceutical Industries Inc.Cequa$714$12,81411 claims
AlconSimbrinza$160$4,15214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,778 optometrist providers in California.

Other optometrist in Lindsay

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →